Astellas Pharma
A Japanese multinational pharmaceutical company formed through the 2005 merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical.
Last updated October 27, 2026
AI crawler reads
1requests
1companies- Anthropic1
- Profile
- 1
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
Since Oct 28, 2026 · from this site's server log
Overview
Astellas Pharma Inc. is a Japanese multinational pharmaceutical company headquartered in Tokyo. It was created on 1 April 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical, two established Japanese drugmakers with roots extending back to the late nineteenth and early twentieth centuries. The merger combined Yamanouchi's strengths in prescription medicines and international commercial operations with Fujisawa's research capabilities and overseas presence, creating a company with a substantially broader global platform. The company's business is centered on innovative prescription medicines. Its historically important therapeutic franchises have included urology, transplantation and immunology, oncology, infectious disease, cardiology, and selected specialty-care markets. Astellas has developed and commercialized medicines both independently and through partnerships, frequently working with companies such as Pfizer, Gilead Sciences, Roche and Theravance. Its products have included treatments for prostate and bladder cancers, organ-transplant rejection, overactive bladder, fungal infections, anemia associated with chronic kidney disease, menopause-related vasomotor symptoms, and other conditions. Among the company's best-known products are Xtandi, an androgen-receptor inhibitor for prostate cancer commercialized with Pfizer; Prograf and related tacrolimus products for prevention of organ-transplant rejection; Vesicare and Myrbetriq for overactive bladder; Xospata for certain acute myeloid leukemia cases; Padcev for bladder cancer; Cresemba and Mycamine for serious fungal infections; and Veozah for menopause-related hot flashes. Product rights, labels, geographic availability and marketing arrangements vary by jurisdiction, and some older products continue to carry legacy brand identities from the predecessor companies or earlier commercial partnerships. Astellas has pursued growth through internal discovery, licensing, collaborations and acquisitions. Major transactions have expanded its oncology, regenerative medicine, genetic regulation, cell therapy, neuromuscular and ophthalmology capabilities. Notable deals include the 2010 acquisition of OSI Pharmaceuticals, the 2015 purchase of Ocata Therapeutics, the 2016 acquisition of Ganymed Pharmaceuticals, the 2019 acquisition of Audentes Therapeutics and Xyphos Biosciences, and the 2023 acquisition of Iveric Bio. The company has also acquired or partnered with smaller biotechnology businesses to strengthen its pipeline in areas such as women's health, rare disease, gene therapy and age-related disease. The company operates research and development facilities in Japan, North America and Europe, while clinical-development activities have been associated with locations including Northbrook and La Jolla in the United States and Leiden in the Netherlands. Its public identity emphasizes research-led innovation and the ability to improve patients' lives. Astellas has used the English slogan "Leading Light for Life" and the Japanese expression "Ashita wa kaerareru," commonly rendered as "Changing Tomorrow." It remains an active, publicly listed pharmaceutical group with a global commercial and research footprint.
History
Astellas's corporate history combines the development of Fujisawa Pharmaceutical and Yamanouchi Pharmaceutical. Fujisawa Shoten was established in Osaka in 1894 by Tomokichi Fujisawa and adopted the Fujisawa Pharmaceutical name in 1943. Yamanouchi Yakuhin Shokai was founded in Osaka in 1923 by Kenji Yamanouchi; it became Yamanouchi Pharmaceutical in 1940 and relocated to Tokyo in 1942. Both predecessor companies built international operations during the postwar expansion of the Japanese pharmaceutical industry. Fujisawa opened an office in Taiwan in 1962, while Yamanouchi established a Taiwan presence in 1963. Both later developed operations in the United States and Europe from the late 1970s onward. Their internationalization provided the commercial and regulatory infrastructure that later supported Astellas's global business. Fujisawa expanded through acquisitions, including the 1990 purchase of Lyphomed, which helped establish a U.S. research center in Deerfield, Illinois. Yamanouchi strengthened European research through its 1991 acquisition of the pharmaceutical division of Royal Gist Brocades and established a research center in Leiderdorp in the Netherlands. These moves contributed to the scientific and geographic capabilities that the merged company inherited. The two companies completed a merger of equals on 1 April 2005, creating Astellas Pharma. The new company initially combined the predecessor organizations' commercial portfolios and research programs, while some established products continued to use legacy names because of their recognition among physicians and patients. Astellas subsequently pursued a strategy based on selected therapeutic areas, internal research, external innovation and business development. A major step in this strategy was the 2010 acquisition of OSI Pharmaceuticals, which strengthened oncology and added a substantial U.S. research and commercial presence. During the following decade Astellas expanded its partnership and acquisition activity across regenerative medicine, oncology, women's health, rare disease, neuromuscular conditions, gene therapy and ophthalmology. Transactions involving Ocata, Ganymed, Ogeda, Mitobridge, Quethera, Potenza, Audentes, Xyphos, iota Biosciences and Iveric Bio illustrate the company's effort to supplement its traditional small-molecule portfolio with biologics, cell therapies, genetic regulation technologies and specialty medicines. The company has also reshaped its portfolio through divestitures and product transfers. In 2015 it agreed to sell its dermatology business to LEO Pharma, and in 2017 it transferred a group of medicines to LTL Pharma. In the United Kingdom, distribution arrangements for Prograf and Advagraf were adjusted after complaints about product availability, moving from a narrower arrangement to a structure involving multiple wholesalers. Astellas's modern business has been organized around franchises including oncology, urology, immunology and transplantation, cardiology and infectious disease, with research priorities also extending to areas such as diabetes, gastrointestinal disorders and central nervous system diseases. Research infrastructure has included sites in Japan, the United States and Europe, while clinical development has been conducted through international networks. The company remains a publicly listed Japanese pharmaceutical group with worldwide operations.
- 2023
Iveric Bio acquisition announced
[1]Astellas announced the acquisition of Iveric Bio to expand its ophthalmology business.
- 2019
Audentes and Xyphos added
[1]Astellas announced the Audentes acquisition and acquired Xyphos Biosciences, adding gene-therapy and engineered-cell-control capabilities.
- 2015
Ocata acquisition announced
[1]Astellas announced its purchase of Ocata Therapeutics to expand regenerative medicine.
- 2010
OSI Pharmaceuticals acquired
[1]Astellas completed its acquisition of OSI Pharmaceuticals, reinforcing oncology.
- 2005
Astellas Pharma formed
[1]Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical merged on 1 April 2005.
- 1990
Fujisawa acquires Lyphomed
[1]The acquisition supported Fujisawa's U.S. research and operating platform.
- 1923
Yamanouchi predecessor founded
[1]Kenji Yamanouchi founded Yamanouchi Yakuhin Shokai in Osaka.
- 1894
Fujisawa predecessor founded
[1]Tomokichi Fujisawa established Fujisawa Shoten in Osaka, creating the predecessor of Fujisawa Pharmaceutical.
Products and positioning
A global research-based pharmaceutical company focused on innovative prescription medicines and specialty-care therapies.
Oncology
Xtandi
Enzalutamide, an androgen-receptor signaling inhibitor used in the treatment of prostate cancer. The product is commercialized through a collaboration with Pfizer and is one of Astellas's most prominent oncology brands.
Transplantation and immunology
Prograf and Advagraf
Tacrolimus-based products used to help prevent rejection after organ transplantation. The products have been marketed in different formulations and regions, with packaging and labeling changes made after European dosing-error concerns.
Urology
Vesicare
Solifenacin succinate, a treatment for overactive bladder symptoms. Vesicare is one of the legacy products associated with Astellas's longstanding urology franchise.
Urology
Myrbetriq
Mirabegron, a medicine for overactive bladder. Brand ownership and commercialization arrangements differ by market; Astellas has marketed it in the United States while Pfizer has marketed it in certain other territories.
Oncology
Padcev
Enfortumab vedotin, an antibody-drug conjugate used in bladder-cancer treatment. It represents Astellas's focus on targeted oncology therapies and is commercialized through collaboration.
Oncology
Xospata
Gilteritinib, a targeted oncology medicine associated with treatment of certain acute myeloid leukemia cases involving specific molecular abnormalities.
Anti-infective
Cresemba
Isavuconazole, an antifungal medicine used for serious invasive fungal infections. It is part of Astellas's anti-infective portfolio and has been commercialized through regional arrangements.
Women's health
Veozah
Fezolinetant, a nonhormonal treatment for menopause-related vasomotor symptoms such as hot flashes. The product originated from the Ogeda acquisition and broadened Astellas's specialty-care presence.
Anti-infective
Mycamine
Micafungin sodium, an echinocandin antifungal used against serious fungal infections.
Immunology and dermatology
Protopic
Tacrolimus ointment used in the management of atopic dermatitis and related eczema conditions.
Controversies
2023
Employee detention in China
Astellas reported that an employee had been detained by Chinese authorities on alleged espionage grounds. The Japanese government criticized the detention as arbitrary.
2020
Astellas files patent-infringement complaint against pharmaceutical companies
Astellas Pharma Inc. and affiliated plaintiffs filed a complaint in Delaware against 21 pharmaceutical companies. The complaint alleged that the companies' proposed generic versions of Myrbetriq would infringe the '780 patent. The plaintiffs sought relief from the court. These allegations are claims made in the complaint and have not been established as findings.
2019
Medicare copay-foundation settlement
Astellas agreed to pay $100 million to resolve U.S. Department of Justice allegations that it had conspired to provide improper kickbacks through Medicare copay foundations.
2018
Research-funding and clinical-protocol reprimand
The Prescription Medicines Code of Practice Authority reported concerns about research funding awarded to a senior clinician and about Astellas's failure to provide investigators with sufficient and timely information after a hospital protocol was later abandoned.
2017
Suspension extended over oversight and promotional-material findings
The industry suspension was extended after findings concerning nurse oversight and training and incomplete prescribing information. Astellas was also reprimanded over promotional materials for several medicines that lacked required safety information.
2016
United Kingdom industry-code suspension
The Association of the British Pharmaceutical Industry suspended Astellas for a year after findings that the company had not fully disclosed the nature of a meeting described as an advisory board and had misled the relevant medicines-code authority.
2009
Tacrolimus packaging and labeling concerns in Europe
Prograf and Advagraf were reported to be susceptible to dosing errors in Europe, with serious adverse reactions reported among some patients. Packaging and labeling were subsequently corrected following a warning from the United Kingdom medicines regulator.
Marketing campaigns
- Leading Light for Life
International
Astellas's English corporate slogan, expressing its positioning around scientific innovation and improving patients' lives.
- Changing Tomorrow
Japan
The Japanese corporate expression "Ashita wa kaerareru" presents the company as working to change future health outcomes through medicines and research.
Brand decisions
2023
Acquisition of Iveric BioM&ABackground
Astellas pursued expansion in ophthalmology and retinal disease.
Action taken
The company announced an agreement to acquire Iveric Bio for approximately $5.9 billion.
Aftermath
The transaction strengthened Astellas's ophthalmology portfolio and late-stage specialty pipeline.
Transaction value. Approximately $5.9 billion (2023)
2019
Acquisition of Audentes TherapeuticsM&ABackground
Astellas wanted to build a substantial genetic-regulation and gene-therapy business.
Action taken
Astellas agreed to acquire Audentes for approximately $3 billion in cash and planned to operate it as a wholly owned center of excellence.
Aftermath
Audentes became part of Astellas's genetic-regulation activities, while the transaction also brought manufacturing and development capabilities for AAV programs.
Transaction value. Approximately $3 billion (2019)
2015
Acquisition of Ocata TherapeuticsM&ABackground
Astellas sought to broaden its capabilities in regenerative medicine.
Action taken
The company announced the acquisition of Ocata Therapeutics, formerly Advanced Cell Technology.
Aftermath
The transaction was completed in February 2016 and added a regenerative-medicine platform.
2010
Acquisition of OSI PharmaceuticalsM&ABackground
Astellas aimed to strengthen its oncology business and U.S. research platform.
Action taken
Astellas acquired OSI Pharmaceuticals in a transaction reported at approximately $4 billion.
Aftermath
The deal expanded Astellas's oncology capabilities and presence in the United States.
Transaction value. $4 billion (2010)
2005
Merger of Yamanouchi and FujisawaM&ABackground
The two companies sought to combine their Japanese and international pharmaceutical businesses.
Action taken
They completed a merger of equals and began operating as Astellas Pharma on 1 April 2005.
Aftermath
The transaction created a global pharmaceutical group with combined research, commercial and international capabilities.
Recent events
Astellas files patent-infringement complaint against pharmaceutical companies[3]
Reported:
Astellas Pharma Inc. and affiliated plaintiffs filed a complaint in Delaware against 21 pharmaceutical companies, alleging that their proposed generic versions of Myrbetriq would infringe the ’780 patent. The plaintiffs sought court relief; the allegations are claims in the complaint.
- Unconfirmed
Astellas and University of Pittsburgh enter dry-AMD research collaboration[4]
Reported:
Astellas Pharma entered into a research collaboration agreement with the University of Pittsburgh to discover and optimize clinical candidates for dry age-related macular degeneration using an AAV-based gene therapy approach.
Astellas and Adaptimmune agree to develop T-cell therapies[5]
Reported:
Astellas Pharma and Adaptimmune said they would select three molecular targets and develop T-cell-based therapies against them, including CAR-T and T-cell receptor therapies. Astellas agreed to pay $50 million upfront and up to $897 million in milestone payments.
Astellas acquires Xyphos Biosciences[6]
Reported:
Astellas Pharma acquired Xyphos Biosciences for up to $665 million. Astellas paid $120 million at closing, and Xyphos became a wholly owned subsidiary of Astellas.
Sources8 sources
- 1Astellas Pharmaen.wikipedia.org
- 2Astellas Pharma official websiteastellas.com
- 3Astellas files patent-infringement complaint against pharmaceutical companieslawstreetmedia.com
- 4安斯泰来与匹兹堡大学开展干性AMD研究合作thepharmaletter.com
- 5Astellas与Adaptimmune达成开发T细胞疗法合作medcitynews.com
- 6安斯泰来收购Xyphos Biosciencesgenengnews.com
- 7Astellas Acquires Xyphos to Boost Immuno-oncology Pipelinefinance.yahoo.com
- 8Astellas partners with Adaptimmune to develop off-the-shelf CAR-T and T-cell therapieshealio.com
Cite this profile: Cite the canonical profile. /brand-wiki/astellas-pharma · Editorial policy · How profiles are compiled